Nitroimidazo-oxazole compound dndi-vl-2098: An orally effective preclinical drug candidate for the treatment of visceral leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 518-527

  Gupta, Suman ^a   Yardley, Vanessa ^b   Vishwakarma, Preeti ^a   Shivahare, Rahul ^a   Sharma, Bhawna ^c   Launay, Delphine ^d   Martin, Denis ^d   Puri, Sunil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^d DND i (Drugs for Neglected Diseases Initiative)   (Switzerland)

Author keywords

Chemotherapy; Hamster; Mouse; Nitroimidazoles

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DNDI VL 2001; DNDI VL 2002; DNDI VL 2003; DNDI VL 2005; DNDI VL 2006; DNDI VL 2010; DNDI VL 2011; DNDI VL 2013; DNDI VL 2014; DNDI VL 2015; DNDI VL 2016; DNDI VL 2017; DNDI VL 2018; DNDI VL 2019; DNDI VL 2028; DNDI VL 2029; DNDI VL 2032; DNDI VL 2034; DNDI VL 2045; DNDI VL 2046; DNDI VL 2047; DNDI VL 2048; DNDI VL 2053; DNDI VL 2060; DNDI VL 2098; MILTEFOSINE; NITROIMIDAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIPROTOZOAL AGENT; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEISHMANIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENANTIOMER; FEMALE; GIEMSA STAIN; GROWTH INHIBITION; HAMSTER MODEL; IN VITRO STUDY; LEISHMANIA BRAZILIENSIS; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIA TROPICA; MALE; MOUSE; NONHUMAN; RACEMIC MIXTURE; REAL TIME POLYMERASE CHAIN REACTION; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; DRUG SENSITIVITY; HAMSTER; HUMAN; IC50; LEISHMANIASIS, VISCERAL; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITROIMIDAZOLES; PARASITIC SENSITIVITY TESTS; TIME FACTORS;

EID: 84922470049     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku422     Document Type: Article

References (26)

1. WHO. Report of the First Meeting of WHOStrategic and Technical Advisory Group on Neglected Tropical Diseases, Geneva, 2007. http://whqlibdoc.who. int/hq/2007/WHO_CDS_NTD_2007.2_eng.pdf.
2. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 2005; 18: 293-305.
3. den Boer M, Argaw D, Jannin J et al. Leishmaniasis impact and treatment access. Clin Microbiol Infect 2011; 17: 1471-7.
4. Drugs for Neglected Diseases initiative. Target Product Profile for VL. http://www.dndi.org/diseases-projects/diseases/vl/tpp/tpp-vl.html.
5. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14: 150-64.
6. Malanga CM, Conroy J, Cuckler AC. Therapeutic efficacy of several nitroimidazoles for experimental Trypanosoma cruzi infections in mice. J Parasitol 1981; 67: 35-40.
7. Thompson AM, Sutherland HS, Palmer BD et al. Synthesis and structureactivity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5himidazo[ 2,1-b][1,3]oxazine (PA-824). J Med Chem 2011; 54: 6563-85.
8. TB Alliance. PA-824: Meeting Milestones. 2003. http://tballiance.org/ newscenter/view-brief.php?id=67.
9. Mital A. Synthetic nitroimidazoles: biological activities and mutagenicity relationships. Sci Pharm 2009; 77: 497-520.
10. Croft SL, Yardley V. Animal models of visceral leishmaniasis. In: Zak O, ed. Handbook of Animal Models of Infection. New York: Academic Press, 1999; 783-7.
11. Shivahare R, Korthikunta V, Chandasana H et al. Synthesis, structureactivity relationships and biological studies of chromenochalcones as potential antileishmanial agents. J Med Chem 2014; 57: 3342-57.
12. Mohamed-Ahmed AH, Seifert K, Yardley V et al. Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(a-glutamic acid) complex. Antimicrob Agents Chemother 2013; 57: 4608-14.
13. Kaiser M, Bray MA, Cal M et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 2011; 55: 5602-8.
14. Yardley V, Gamarro F, Croft SL. Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine. Antimicrob Agents Chemother 2010; 54: 5356-8.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
16. HuberW, Koella JC. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 1993; 55: 257-61.
17. Yardley V, Khan AA, Martin MB et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother 2002; 46: 929-31.
18. Shivahare R, Vishwakarma P, Parmar N et al. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cellmediated immunity during experimental visceral leishmaniasis. PLoS One 2014; 9: e94596.
19. Gupta R, Kushawaha PK, Samant M et al. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses. J Antimicrob Chemother 2012; 67: 440-3.
20. Tiuman TS, Santos AO, Ueda-Nakamura T et al. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15: e525-32.
21. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 2011; 17: 1478-83.
22. Wyllie S, Patterson S, Stojanovski L et al. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Sci Transl Med 2012; 4: 119re1.
23. Patterson S, Wyllie S, Stojanovski L et al. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis. Antimicrob Agents Chemother 2013; 57: 4699-706.
24. Wilson ME, Jeronimo SM, Pearson RD. Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 2005; 38: 147-60.
25. Melby PC, Chandrasekar B, Zhao W et al. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 2001; 166: 1912-20.
26. Nieto A, Dominguez-Bernal G, Orden JA et al. Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model. Vet Res 2011; 42: 39.